From Casetext: Smarter Legal Research

Strumph v. Schering Corp.

Supreme Court of New Jersey
Jul 13, 1993
133 N.J. 33 (N.J. 1993)

Summary

adopting Judge Skillman's dissent

Summary of this case from Baker v. APP Pharms. LLP

Opinion

Argued March 2, 1993 —

Decided July 13, 1993.

Appeal from Superior Court, Appellate Division.

Russell L. Hewit argued the cause for appellant ( Dughi and Hewit, attorneys; Mr. Hewit, Christopher J. Christie, and Mary Elizabeth Gazi, on the briefs).

Earl G. Kauffman, a member of the Pennsylvania bar, argued the cause for respondent ( Jack E. Milkis, attorney; Mr. Kauffman and Mr. Milkis, on the brief).

John B. Kearney submitted a brief on behalf of amicus curiae Pharmaceutical Manufacturers Association ( Kenney Kearney, attorneys).


The judgment is reversed, substantially for the reasons expressed in Judge Skillman's dissenting opinion for the Appellate Division, reported at 256 N.J. Super. 309, 323, 606 A.2d 1140 (1992).


I would affirm the judgment below substantially for the reasons stated by the majority of the Appellate Division, 256 N.J. Super. 309, 606 A.2d 1140 (1992). I write only to emphasize the special significance of the learned-intermediary doctrine in this case. The theory of that doctrine is that a pharmaceutical manufacturer has no independent duty to warn patients of the side effects of medication. The manufacturer's duty is to warn the physician, the learned intermediary, who in turn is presumed by the law to have informed the patient of the side effects. Niemiera v. Schnieder, 114 N.J. 550 , 555 A.2d 1112 (1989). Just as we apply an "objective test" to evaluate the informed-consent rights of the patient in terms of what a prudent person in the patient's position would have done if suitably informed of the risks of treatment, Largey v. Rothman, 110 N.J. 204, 216, 540 A.2d 504 (1988), we should apply an objective test to evaluate what a prudent physician would have done if informed of the risks of this medication. This case presents a factual issue on whether a prudent physician would have informed plaintiff of the side effects of her medication. See Bravman v. Baxter Healthcare Corp., 984 F.2d 71, 75 (2nd Cir. 1993) (holding that a question on proximate cause remained for resolution despite testimony by doctor that if he had been informed by healthcare company of defect in mechanical heart valve he still would not have warned patient).

For reversal — Chief Justice WILENTZ and Justices CLIFFORD, HANDLER and STEIN — 4.

For affirmance — Justice O'HERN — 1.


Summaries of

Strumph v. Schering Corp.

Supreme Court of New Jersey
Jul 13, 1993
133 N.J. 33 (N.J. 1993)

adopting Judge Skillman's dissent

Summary of this case from Baker v. APP Pharms. LLP

reversing substantially for the reasons stated in the dissent

Summary of this case from DiGiovanni v. Saker Shop Rites, Inc.

reversing for reasons expressed in Judge Skillman's dissent

Summary of this case from Perez v. Wyeth Labs., Inc.

In Strumph v. Schering Corp., 133 N.J. 33 (1993), a pharmaceutical liability case similar to the one presently before the court, the New Jersey Supreme Court determined that the trial court properly granted summary judgment to the drug manufacturer on the basis of plaintiff's failure to demonstrate that an adequate warning would have prevented her harm.

Summary of this case from Appleby v. Glaxo Wellcome, Inc.

In Strumph v. Schering Corp., 133 N.J. 33, 626 A.2d 1090, 1090 (1993), the New Jersey Supreme Court reversed the intermediate appellate court's denial of summary judgment to the manufacturer of Trilafon, and in doing so, it adopted the reasons stated in the dissenting opinion of the intermediate court.

Summary of this case from Motus v. Pfizer Inc.

In Strumph, there was unrebutted testimony from the plaintiff's treating physicians that they would have prescribed a particular neuroleptic medication, Trilafon, even had a more detailed and specific warning about a serious side effect been given.Strumph v. Schering Corp., 256 N.J.Super. 309, 606 A.2d 1140 (App.Div. 1992), rev'd on dissent, 133 N.J. 33, 626 A.2d 1090 (1993).

Summary of this case from In re Diet Drug Litig.
Case details for

Strumph v. Schering Corp.

Case Details

Full title:NANCY STRUMPH, PLAINTIFF-RESPONDENT, v. SCHERING CORPORATION…

Court:Supreme Court of New Jersey

Date published: Jul 13, 1993

Citations

133 N.J. 33 (N.J. 1993)
626 A.2d 1090

Citing Cases

In re Diet Drug Litig.

This is so, according to Wyeth, because shortly before it decided Coffman, the Supreme Court reversed the…

Motus v. Pfizer Inc.

It follows that the inclusion of adequate warnings in that information would not have affected his decision.…